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= Abstract  =Korea is one of the endemic areas of chronic hepatitis B virus (HBV) 
infection. To investigate the relative etiologic role of HBV and hepatitis C virus 
(HCV) in chronic liver diseases (CLD) including hepatocellular carcinoma (HCC) 
among age-specific groups in Korea, we enrolled consecutively 6 7 3  patients with 
chronic active hepatitis (CAH), 6 7 7  patients with liver cirrhosis (LC) and patients 
with HCC who had been diagnosed in the liver unit a t  Seoul National University 
Hospital. HBsAg a n d  anti-HCV were  tes ted  using commercially available 
radioimmunoassay and enzyme immunoassay kits, respectively. From this study, 
we were reached a t  suggestion for the possible presence of non-B, non-C type 
CLD agent(s) by exclusion method. The prevalence rates of HBsAg were 45.3%, 
62.5% and 69.3% in patients with CAH, LC and HCC, respectively. The general 
prevalence rates of anti-HCV in patients with CAH, LC and HCC were 27.3%, 19. 
6 %  and 17%, respectively, and, however, in HBsAg-negative patients with CAH, 
LC and HCC those were 48.1%, 46.1% and 42.7%, respectively. The coinfection 
rates of HBV and HCV in patients with CAH, LC and HCC were 1%, 2.4% and 3. 
9%, respectively. The rates of CAH, LC and HCC patients who were negative for 
both HBsAg and anti-HCV and therefore, serologically classified as non-B, non-C 
type were 28.4%, 20.2% and  17.6%, respectively. There was a significant 
differeence in mean age between B- and C-type, and B and non-B, non-C type 
patients with CAH (41.7 vs 54.5 and 50.4 years), LC (48.5 vs 60.1 and 54.9 
years) and HCC (5  1.6 vs 60.4 and 56.1 years) (p < 0.001, respectively). Before 
the age of 50 ,  the etiology of CAH and LC was almost exclusively HBV, while 
over the  age  of 5 0 ,  the  etiologic role of HCV and non-B, non-C was more 
predominant than that of HBV. In elderly (older than 60 years of age) patients 
even with HCC, HCV played an  etiologic role as important as HBV. 
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In conclusion, HBV is the most common etiologic agent of CLD in Korea. 
However, HCV and non-B, non-C infection is a more important etiology in elderly 
patients with CLD older than 50 years of age. 
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The diagnosis of HCC was made by 1 ) presence 
l NTRODUCT l ON of a mass lesion on ultrasonogram and/or CT 
scan of the liver with significant elevation of 
The development of an assay for circulating serum alpha-fetoprotein (AFP) levels (Lee et a/. 
antibodies against hepatitis C virus (anti-HCV) 1991), 2) typical angiographic findings (Kido et 
has now made possible the serological 
diagnosis of chronic liver disease (CLD) type C 
among non-A, non-B (NANB) CLD (Kuo et a/. 
1989). The anti-HCV test has confirmed that 
HCV is frequently involved in the patients with 
chronic NANB hepatitis in Western countries 
(Kuo et a / .  1989; Di Bisceglie et a / .  1989; 
Roggendorf et a/. 1989) and Japan (Nishioka 
1991 ).  
In a previous study (Kim et a/. 1992), we 
showed that the mean age of HBsAg-positive 
patients with CLD was significantly lower than 
that of HBsAg-negative (NANB) patients with 
CLD. In clinical practice, we suspected that anti- 
HCV-posit ive CLD's were more frequently 
observed in elderly patients. 
a/. 1971) with or without significant elevation of 
AFP levels, 3)  liver needle b iopsy under 
peritoneoscopy or ultrasonography. The patients 
who supposedly were thought to be related to 
alcohol and drugs were eliminated. 
2. Serological  tests 
The sera which had been collected at the 
time of diagnosis and stored at -20°C were 
tested for HBsAg and anti-HCV, using 
commercially available radioimmunoassay and 
enzyme immunoassay kits (AUSRIA-II and HCV 
EIA Abbot t  Laboratories, Chicago IL,  
respectively). Non-B, non-C type CLD was 
classified for those who were negative for both 
HBsAg and anti-HCV. 
This study was to investigate the relative 
etiologic role of HBV, HCV and non-6, non-C 3. Stat is t ica l  analysis 
agents in CLD inc luding hepatocellular Statistical analyses were conducted with 
carcinoma (HCC) among age-specific groups in Student t-test and ~ 2 - t e s t  using SPSS/PC+ 
Korea. (Microsoft Corp). 
MATERIALS AND METHODS 
1. Patients 
We enrolled consecutively 673 patients with 
chronic active hepatitis (CAH), 677 patients with 
liver cirrhosis (LC) and 336 patients with HCC 
who had been diagnosed in the liver unit at 
Seoul National University Hospital .  The 
demographic characteristics of the patient are 
shown in Table 1 .  The diagnosis of CAH was 
mostly made by liver biopsy, and that of LC by 
liver biopsy under peritoneoscopy and/or by 
clinical manifestations of portal hypertension. 
Table 1. Demographic characteristics of the patients 
with chron~c active hepatitis (CAH), liver 
cirrhosis (LC) and hepatocellular carcinoma 
(HCC) 
. . . .- - . - - - - -  
C AH LC HCC 
~ - -- - - - 
Number 673 677 336 
Sex (MIF) 4.1:1 3.2: 1 5.9: 1 
Mean age+SD 47.7k11.3 51.9k10.1 53.7k9.1 
Range 16-78 17-81 28-83 
- - -- 
RESULTS 
1. Prevalence of  HBsAg and anti'-HCV, 
and non-B, non-C related CLD 
The positive rates for HBsAg and/or anti- 
HCV and the negative rates for both HBsAg and 
anti-HCV are shown in Table 2. The general 
prevalence rates of anti-HCV, however, in 
patients with CAH, LC and HCC were 27.3%, 19. 
6% and 17.0%, respectively, (not shown in 
table), and those in HBsAg-negative patients 
with CAH, LC and HCC were 48.1 %, 46.1 % and 
42.7%, respectively. The coinfection rates of 
both HBV and HCV in patients with CAH, LC and 
HCC were 1.0%, 2.4% and 3.9%, respectively, 
(not shown in table). The rates of CAH, LC and 
HCC patients who were negative for both HBsAg 
and anti-HCV and therefore, serologically 
classified as non-B, non-C type were 28.4%, 20. 
2% and 17.6%, respectively. 
2. Age  d i s t r i b u t i o n  o f  HBsAg-, an t i -  
HCV-posi t ive and both negative pat ients 
The mean age of each type of CLD is shown 
in Table 3. There was a significant difference in 
mean age between 6- and C-type and B- and 
non-0, non-C patients with CAH, LC and HCC 
(p<0.001, respectively). However, there was no 
such difference between C and non-B, non-C 
Table 2. HBsAg and anti-HCV positivity in patients with chronic active hepatitis (CAH), liver cirrhosis (LC) and 
hepatocellular carcinoma (HCC) 
HBsAg-positive HBsAg-negative 
- -- . -.  -.  - 
anti-HCV(+) anti-HCV(+) anti-HCV(-) 
No.(% in total)* No.(%)** No.(% in total)* No.(%)*** No.(% in total)* 
-. .. . -- 
CAH (n=673) 305(45.3%) 7(2.3%) 368(54.7%) 177(48.1%) 191 (28.4%) 
LC (n=677) 423(62.5%) 16(3.8%) 254(37.5%) 1 17(46.l%) 137(20.2%) 
HCC (n=336) 233(69.3%) 13(5.6%) 103(30.7%) 44(42.7%) 59(17.6%) 
-- - - - -. - - .- -  . .- . - 
* : The denominator is the number of all patients with each type of CLD. 
* *  : The denominator is the number of HBsAg-positive patients with each type of CLD. 
*** : The denom~nator is the number of HBsAg-negative patients with each type of CLD. 
Table 3. Mean ages of the patients w~th chronic active hepatitis (CAH), liver cirrhosis (LC) and hepatocellular 
carcinoma (HCC) according to serological status of HBsAg and anti-HCV 
... -- .. -- -  - -- - 
TY pes Serology CAH LC HCC 
-- -- - - ~ - -- - - --- - . . - .- 
B HBsAg (+) Age (M+SD) 41.7+9.6* 48.5*9.0* 51.6*7.9* 
Range 16-73 17-74 29-71 
M/F 6.6: 1 3.6: 1 6.5: 1 
--  ~.~ - ~ -~ - - -- 
C Anti-HCV (+) Age (MkSD) 54.5+ 10.2** 60.1 *7.9** 60.4*7.2** 
Range 20-78 39-8 1 41 -75 
M/F 2.7: l  2.0: 1 5.3: 1 
- - - . -  - --  - -. - .  - - . . . .. - . - -- -. 
Non-B, non-C HBsAg (-) and Age (M+SD) 50.4* 1 O.O*** 54.9*9.5*** 56.1 * 1 1.4*** 
anti-HCV(-) Range 20-76 25-73 28-83 
M/F 3.2: 1 3.7: 1 4.4: 1 
-- - - -  - -. ~ . - - - . - . -- . -- - 
p values between * and '* < 0.001 
p values between * and ** *  < 0.001 
type (p>0 .05) .  Figure 1 shows the clear 
difference in the age distribution between 
HBsAg-positive and anti-HCV-positive patients 
with CAH, LC and HCC, respectively; anti-HCV- 
positive patients in each panel were distributed 
at more elderly groups than HBsAg-positive 
patients. Figure 2 shows the relative etiologic 
role of HBV and HCV in each age-specific 
group. Before the age of 50, the etiology of CAH 
and LC was almost exclusively HBV, while over 
the age of 50, the etiologic role of HCV is more 
predominant than that of HBV. In patients older 
than 60 years of age even with HCC, HCV 
played an etiologic role as important as HBV. 
DISCUSSION 
In this study, we could clearly demonstrate 
the etiologic profile of chronic liver diseases 
including HCC in Korea; HBV is the most 
common cause of chronic liver diseases and 
HCV also played a significant etiologic role in 
CLD in Korea. The prevalence rates of anti-HCV- 
posit ivity in HBsAg-negative (NANB type) 
patients with CLD observed in the present study 
was lower than those obserbved in European 
countries and Japan where HBV infection is 
relatively less prevalent and, was comparable to 
those reported in Taiwan which is one of theoHBV 
endemic areas. The reason why the anti-HCV 
positive rate in each CLD in HBV endemic areas 
was lower than that in less prevalent areas of 
HBV still remains to be further investigated. One 
explanation may be that a significant proportion 
of HBsAg-negative (therefore, serologically 
classified as NANB) patients in HBV endemic 
areas might be HBV related, which has been 
proven by the presence of HBV DNA in their sera 
in our previous study (Lee et a/. 1992). 
Chuang(Chuang et a/. 1992) in Taiwan as 
well as Bruix (Bruix et a / .  1989) in Spain 
observed a higher prevalence of coinfection of 
HBsAg and anti-HCV in patients with HCC than 
in patients with other CLD's; thus, they reported 
that the patients coinfected with HBV and HCV 
were more likely to develop HCC than patients 
with either agent alone, suggest ing the 
combined oncogenic action of both viruses. 
However, the low rate of coinfection of HBV and 
HCV (3.9% of total patients with HCC) observed 
in the present study d id  not support their 
hypothesis. 
One fifth to one fourth of all CLD patients 
had neither HBsAg nor anti-HCV reactivity, thus 
thought to be and classified as non-B, non-C 
type. The negative reaction may be due to lack 
of sensitivity of the test currently available for 
HBV or HCV. To assess the etiologic role of HBV 
and HCV in non-B, non-C CLD's, detection of 
serum HBV DNA and HCV RNA using (reverse- 
transcriptase) polymerase chain reaction is 
warranted. However, we can not now exclude 
the possible involvement of an unveiled hepatitis 
virus in these patients. 
The present study proved our hypothesis to 
be true that the mean age of HBsAg-positive 
patients with each type of CLD is younger than 
that of anti-HCV-positive. A possible explanation 
for the difference is that chronic NANB hepatitis 
was a much slower process than chronic 
hepatitis B (Okuda et a/. 1984), and CLD, NANB 
appeared clinically indolent even if histologically 
manifested (Alter 1990); therefore, HCV infection 
took longer to lead to advanced disease which 
was clinically manifested. Another explanation 
might be that it is due to the acquisition of the 
infection at different ages; HBV infection is 
mostly acquired vertically in the perinatal period 
(Nishioka 1984) and HCV infection sporadically 
during adult life (Dienstag and Alter 1986). 
However, the cause of the difference still remains 
to be clarified. 
Of interest in this study is that HCV played a 
no less important etiologic role than HBV in 
elderly patients (over the age of 50) even in a 
hepatitis B endemic area. Before the age of 50, 
the etiology of CAH and LC was almost 
exclusively HBV, while over the age of 50, the 
etiologic role of HCV is more predominant than 
that of HBV. In elderly (older than 60 years of 
age) patients even with HCC, HCV played an 
etiologic role as important as HBV. This finding 
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Flg. 1. Comparison of the age d~strbut~on between HBsAg-posltlve and antl-HCV-pos~tlve patlents In each 
chronlc h e r  d~sease A chron~c a c h e  hepatlt~s B llver clrrhosls, C hepatocellular carcinoma 
Fig. 2. Comparison of the positlvtty rate of HBsAg and antl-HCV In age speclflc groups in each chronlc llver 
d~sease. A: chronic act~ve hepatltls, 6: llver c~rrhosls, C hepatocellular carcinoma. 
observed in Korea will possibly be proven to be 
general by further studies in other hepatitis B 
endemic areas such as Taiwan. 
In conclusion, HBV is the most common 
etiologic agent of CLD in Korea. However, HCV 
infection is a more important etiology in elderly 
patients with CLD older than 50 years of age. 
Furthermore, this study would suggest that one 
should look at the other agent(s) when there are 
no HBV or HCV markers. 
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